Skip to main content
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    1-2-1 Meetings / Networking Break
  1. Bi/Multi Specifics
    • Bi/Multispecifics
    Poster Presentation: Solving the Bispecific Antibody Mispairing Challenge in Preclinical R&D
    Successful bispecific antibody production requires the correct assembly of multiple peptide chains t ...
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    Drinks-Canape Reception
  2. Bi/Multispecifics
    • Bi/Multispecifics
    Do complex sequences show an impact on titer, proper assembly, and purification? Do you face issues ...
  3. Formats & Scaffolds
    • Formats & Scaffolds
    Single domain antibodies are incredibly versatile and increasingly appear in clinical pipelines. Wha ...
  4. Lead Identification & Optimization
    • Lead Identification & Optimization
    What are the key issues faced in the in vitro degradation of antibodies, and which (bio)chemical pat ...
  5. Formats & Scaffolds
    • Formats & Scaffolds
    Poster Presentation: Lead Identification & Optimization topic: Amplifying the therapeutic potential of rabbit antibodies by a multi-parametric humanization approach for single-step engineering
    Given the unique biology of antibody maturation in rabbits, this species is an excellent source for ...
  6. Lead Identification & Optimization
    • Lead Identification & Optimization
    Poster Presentation: Accelerating antibody design with a novel AI+physics-based computational framework
    The computational development of antibodies is an emerging industry that has become feasible thanks ...
  7. Antibody Drug Conjugates
    • Antibody Drug Conjugates
    Poster Presentation: Lead Identification & Optimization topic: Pioneer Platform: A Novel Biotherapeutic Antibody Discovery Platform
    The PioneerTM Antibody Discovery Platform is Bio-Rad’s new service for biotherapeutic lead generatio ...
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    Afternoon Refreshments
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    1-2-1 Meetings / Networking Break
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    1-2-1 Meetings / Networking Break
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    Spotlight Presentation: Innovative Solutions Set New Standards in Quality & Speed for Biologics Research
    In today’s biologics drug development landscape, flexible, end-to-end solutions are crucial for adva ...
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    Networking Lunch
  8. Bi/Multispecifics
    • Bi/Multispecifics
    What are the differences between BsAb process development and standard mAbs?
    What are the main driving forces to bring more BsAbs to the market compared to mAbs?  What would be ...
  9. Formats & Scaffolds
    • Formats & Scaffolds
    Lead Identification & Optimization topic: Early immunogenicity risk assessment and functional testing of biotherapeutics
    In silico and in vitro immunogenicity assessment as a de-risking strategy Approaches to mitigate the ...
  10. Lead Identification & Optimization
    • Lead Identification & Optimization
    AI/ML in antibody discovery, engineering and lead optimization
    How can we increase hit diversity from screening outputs using NGS with AI/ML? How can improve antib ...
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    Morning Refreshments
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    1-2-1 Meetings / Networking Break
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    1-2-1 Meetings / Networking Break
  11. Bi/Multispecifics
    • Bi/Multispecifics
    Optimal design for a multispecific TCE - what have we learned and what do we still need to learn? Ho ...
  12. Formats & Scaffolds
    • Formats & Scaffolds
    Optimal rationale design for CIS versus TRANS-potency (target selection, novel masking strategies) A ...
  13. Lead Identification & Optimization
    • Lead Identification & Optimization
    A preponderance of positively-charged residues (R, K) in the paratope of antibodies can lead to poly ...
  14. Antibody Drug Conjugates
    • Antibody Drug Conjugates
    Antigen Heterogeneity: Tumor cells often express various antigens, making it difficult to identify u ...
    Bayer
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    Opening Address & Keynote Presentation: Hydrophilic Click chemistry to widen the therapeutic window of ADCs
    Current ADCs still display poor translation of their preclinical therapeutic window into the clinic, ...
    • Antibody Drug Conjugates
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    Registration